CorMedix (CRMD) Q2 FY26 earnings call

CorMedix delivered a strong second quarter, driven by continued demand for DefenCath and the contribution from the acquired Melinta portfolio. The company is actively navigating the post-TDAPA landscape for DefenCath, securing agreements with all major LDOs and pursuing Medicare Advantage contracts. Significant progress was also made in the pipeline, with positive Phase 3 ReSPECT data for Rezzayo and ongoing efforts for its sNDA submission, alongside advancements in the DefenCath TPN study.